PuSH - Publication Server of Helmholtz Zentrum München

Weidle, U.H.* ; Maisel, D.* ; Eick, D.

Synthetic lethality-based targets for discovery of new cancer therapeutics.

Cancer Genomics Proteomics 8, 159-171 (2011)
Publ. Version/Full Text
Free by publisher
Synthetic lethality is based on the incompatibility of cell survival with the loss of function of two or more genes, not with loss of function of a single gene. If targets of synthetic lethality are deregulated or mutated in cancer cells, the strategy of synthetic lethality can result in significant increase of therapeutic efficacy and a favourable therapeutic window. In this review, we discuss synthetic lethality based on deficient DNA repair mechanisms, activating mutations of RAS, loss of function mutations of the tumor suppressor genes p53, Rb and von Hippel-Lindau, and disruption of interactive protein kinase networks in the context of development of new anticancer agents.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Von--Hippel-Lindau; Negative breast-cancer; Tumor-suppressor gene; Renal-cell Carcinoma; Poly/(ADP-Ribose) Polymerase; Colorecctal-cancer; DNA-repair; C-MYC; Microsatellite instability; Kinase reqirements
ISSN (print) / ISBN 1109-6535
e-ISSN 1790-6245
Quellenangaben Volume: 8, Issue: 4, Pages: 159-171 Article Number: , Supplement: ,
Publisher International Institute of Anticancer Research
Reviewing status Peer reviewed